Project Grant R43AR076842

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA Program 93.859 (Biomedical Research and Research Training) aims to develop a novel topical treatment for burn pain by blocking cutaneous pain receptors. The $340,685 award to Serentrix LLC, a minority-owned for-profit organization, will fund the development of SER114, a topical small molecule antagonist of the TRPV1 receptor, as a treatment for cutaneous burn pain. The innovation lies in targeting...

This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $818,360 to the University of Southern California to develop new angiotensin AT2 receptor antagonists for the treatment of neuropathic pain. The research aims to identify and optimize a novel lead series of highly potent and safe AT2R antagonists that...

This $1,559,917 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to develop a topical neurokinin-1 receptor (NK1R) antagonist as a non-addictive analgesic treatment for chronic ocular pain. The key objectives are to assess the analgesic efficacy of the NK1R antagonist and determine its effects on the ocular surface-trigeminal ganglion neurosensory pathway. The project is...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,804 to Arkayli Biopharma, Inc. to develop a novel topical formulation of a beta blocker as a targeted therapeutic for infantile hemangioma. The key objectives are to: 1) evaluate the effects of the ARK 001 formulation on in-vitro endothelial cell activity, and 2) conduct enabling non-clinical animal pharmacokinetic and toxicity...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop and test optimized formulations of a combination drug therapy for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The $318,488 award will fund feasibility studies in dogs and mice to identify the most desirable pharmacokinetic parameters and...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...

The federal Project Grant award R21CA298918, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development and screening of novel flupirtine analogues for the treatment of chemotherapy-induced neuropathic pain (CINP). The $179,403 grant aims to strategically synthesize potent KV7.2/7.3 activators that can effectively relieve CINP without the hepatotoxicity associated with the flupirtine parent compound. Key objectives include (1)...

The National Eye Institute (NEI) awarded a $590,172 Project Grant under the Vision Research federal grant program (CFDA 93.867) to Vyluma Inc. to develop a safe and effective topically administered pharmacotherapy to treat acute corneal pain. The key products and services to be delivered under this grant include: 1) Pharmacodynamic dose identification studies in a rat model to determine the minimum effective dose of the topical pregabalin formulation NVK032 for treating acute corneal pain; 2)...